vs
安进（AMGN）与NATURAL HEALTH TRENDS CORP（NHTC）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是NATURAL HEALTH TRENDS CORP的1012.0倍（$9.9B vs $9.7M）。安进净利率更高（13.5% vs -6.0%，领先19.5%）。安进同比增速更快（8.6% vs -10.1%）。安进自由现金流更多（$961.0M vs $-964.0K）。过去两年安进的营收复合增速更高（15.1% vs -5.6%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Sword Health是一家数字医疗企业，专注开发针对肌肉骨骼疾病、骨盆健康与损伤预防的物理治疗方案。该企业2015年由Virgílio Bento与Márcio Colunas在葡萄牙创立，将人工智能融入护理模式，提供数字化物理治疗服务。截至2024年，Sword Health已开展国际化运营，在美国、爱尔兰与葡萄牙均设有办公室。
AMGN vs NHTC — 直观对比
营收规模更大
AMGN
是对方的1012.0倍
$9.7M
营收增速更快
AMGN
高出18.7%
-10.1%
净利率更高
AMGN
高出19.5%
-6.0%
自由现金流更多
AMGN
多$962.0M
$-964.0K
两年增速更快
AMGN
近两年复合增速
-5.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $9.7M |
| 净利润 | $1.3B | $-588.0K |
| 毛利率 | 69.8% | 72.9% |
| 营业利润率 | 27.6% | -6.5% |
| 净利率 | 13.5% | -6.0% |
| 营收同比 | 8.6% | -10.1% |
| 净利润同比 | 112.6% | -434.1% |
| 每股收益（稀释后） | $2.45 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNNHTC
| Q4 25 | $9.9B | $9.7M | ||
| Q3 25 | $9.6B | $9.5M | ||
| Q2 25 | $9.2B | $9.8M | ||
| Q1 25 | $8.1B | $10.7M | ||
| Q4 24 | $9.1B | $10.8M | ||
| Q3 24 | $8.5B | $10.7M | ||
| Q2 24 | $8.4B | $10.5M | ||
| Q1 24 | $7.4B | $11.0M |
净利润AMGNNHTC
| Q4 25 | $1.3B | $-588.0K | ||
| Q3 25 | $3.2B | $-431.0K | ||
| Q2 25 | $1.4B | $15.0K | ||
| Q1 25 | $1.7B | $122.0K | ||
| Q4 24 | $627.0M | $176.0K | ||
| Q3 24 | $2.8B | $35.0K | ||
| Q2 24 | $746.0M | $173.0K | ||
| Q1 24 | $-113.0M | $188.0K |
毛利率AMGNNHTC
| Q4 25 | 69.8% | 72.9% | ||
| Q3 25 | 67.8% | 73.7% | ||
| Q2 25 | 67.2% | 73.9% | ||
| Q1 25 | 63.6% | 73.6% | ||
| Q4 24 | 65.7% | 74.2% | ||
| Q3 24 | 61.1% | 74.1% | ||
| Q2 24 | 61.4% | 74.2% | ||
| Q1 24 | 57.0% | 73.4% |
营业利润率AMGNNHTC
| Q4 25 | 27.6% | -6.5% | ||
| Q3 25 | 26.4% | -5.2% | ||
| Q2 25 | 28.9% | -3.4% | ||
| Q1 25 | 14.5% | -3.2% | ||
| Q4 24 | 25.4% | -3.9% | ||
| Q3 24 | 24.1% | -2.6% | ||
| Q2 24 | 22.8% | -2.3% | ||
| Q1 24 | 13.3% | -3.3% |
净利率AMGNNHTC
| Q4 25 | 13.5% | -6.0% | ||
| Q3 25 | 33.7% | -4.5% | ||
| Q2 25 | 15.6% | 0.2% | ||
| Q1 25 | 21.2% | 1.1% | ||
| Q4 24 | 6.9% | 1.6% | ||
| Q3 24 | 33.3% | 0.3% | ||
| Q2 24 | 8.9% | 1.7% | ||
| Q1 24 | -1.5% | 1.7% |
每股收益（稀释后）AMGNNHTC
| Q4 25 | $2.45 | $-0.05 | ||
| Q3 25 | $5.93 | $-0.04 | ||
| Q2 25 | $2.65 | $0.00 | ||
| Q1 25 | $3.20 | $0.01 | ||
| Q4 24 | $1.17 | $0.01 | ||
| Q3 24 | $5.22 | $0.00 | ||
| Q2 24 | $1.38 | $0.02 | ||
| Q1 24 | $-0.21 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $28.9M |
| 总债务越低越好 | $54.6B | — |
| 股东权益账面价值 | $8.7B | $23.4M |
| 总资产 | $90.6B | $38.4M |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNNHTC
| Q4 25 | $9.1B | $28.9M | ||
| Q3 25 | $9.4B | $32.0M | ||
| Q2 25 | $8.0B | $34.2M | ||
| Q1 25 | $8.8B | $41.9M | ||
| Q4 24 | $12.0B | $43.9M | ||
| Q3 24 | $9.0B | $46.3M | ||
| Q2 24 | $9.3B | $48.7M | ||
| Q1 24 | $9.7B | $54.4M |
总债务AMGNNHTC
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNNHTC
| Q4 25 | $8.7B | $23.4M | ||
| Q3 25 | $9.6B | $26.1M | ||
| Q2 25 | $7.4B | $28.9M | ||
| Q1 25 | $6.2B | $30.9M | ||
| Q4 24 | $5.9B | $32.9M | ||
| Q3 24 | $7.5B | $35.3M | ||
| Q2 24 | $5.9B | $37.3M | ||
| Q1 24 | $5.0B | $39.4M |
总资产AMGNNHTC
| Q4 25 | $90.6B | $38.4M | ||
| Q3 25 | $90.1B | $42.3M | ||
| Q2 25 | $87.9B | $45.2M | ||
| Q1 25 | $89.4B | $53.2M | ||
| Q4 24 | $91.8B | $55.4M | ||
| Q3 24 | $90.9B | $58.3M | ||
| Q2 24 | $90.9B | $61.5M | ||
| Q1 24 | $93.0B | $67.6M |
负债/权益比AMGNNHTC
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $-959.0K |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $-964.0K |
| 自由现金流率自由现金流/营收 | 9.7% | -9.9% |
| 资本支出强度资本支出/营收 | 6.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.20× | — |
| 过去12个月自由现金流最近4个季度 | $8.1B | $-6.1M |
8季度趋势，按日历期对齐
经营现金流AMGNNHTC
| Q4 25 | $1.6B | $-959.0K | ||
| Q3 25 | $4.7B | $113.0K | ||
| Q2 25 | $2.3B | $-5.6M | ||
| Q1 25 | $1.4B | $484.0K | ||
| Q4 24 | $4.8B | $88.0K | ||
| Q3 24 | $3.6B | $-436.0K | ||
| Q2 24 | $2.5B | $-3.6M | ||
| Q1 24 | $689.0M | $549.0K |
自由现金流AMGNNHTC
| Q4 25 | $961.0M | $-964.0K | ||
| Q3 25 | $4.2B | $70.0K | ||
| Q2 25 | $1.9B | $-5.6M | ||
| Q1 25 | $980.0M | $468.0K | ||
| Q4 24 | $4.4B | $68.0K | ||
| Q3 24 | $3.3B | $-443.0K | ||
| Q2 24 | $2.2B | $-3.6M | ||
| Q1 24 | $459.0M | $538.0K |
自由现金流率AMGNNHTC
| Q4 25 | 9.7% | -9.9% | ||
| Q3 25 | 44.4% | 0.7% | ||
| Q2 25 | 20.8% | -57.5% | ||
| Q1 25 | 12.0% | 4.4% | ||
| Q4 24 | 48.4% | 0.6% | ||
| Q3 24 | 39.0% | -4.1% | ||
| Q2 24 | 26.5% | -34.2% | ||
| Q1 24 | 6.2% | 4.9% |
资本支出强度AMGNNHTC
| Q4 25 | 6.5% | 0.1% | ||
| Q3 25 | 4.6% | 0.5% | ||
| Q2 25 | 4.0% | 0.0% | ||
| Q1 25 | 5.0% | 0.1% | ||
| Q4 24 | 4.1% | 0.2% | ||
| Q3 24 | 3.0% | 0.1% | ||
| Q2 24 | 2.8% | 0.2% | ||
| Q1 24 | 3.1% | 0.1% |
现金转化率AMGNNHTC
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | -375.67× | ||
| Q1 25 | 0.80× | 3.97× | ||
| Q4 24 | 7.61× | 0.50× | ||
| Q3 24 | 1.26× | -12.46× | ||
| Q2 24 | 3.30× | -20.62× | ||
| Q1 24 | — | 2.92× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
NHTC
暂无分部数据
